Publikationen, an denen er mitarbeitet Miriam Redrado Jordán (8)

2015

  1. Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells

    Prostate, Vol. 75, Núm. 11, pp. 1137-1149

2014

  1. Differential tumor expression of inhibitor of differentiation-1 in prostate cancer patients with extreme clinical phenotypes and prognostic implications

    Clinical Genitourinary Cancer, Vol. 12, Núm. 2, pp. 87-93

  2. Id-1B, an alternatively spliced isoform of the inhibitor of differentiation-1, impairs cancer cell malignancy through inhibition of proliferation and angiogenesis

    Current Molecular Medicine, Vol. 14, Núm. 1, pp. 151-162

2013

  1. Spatial-temporal protein expression of inhibitor of differentiation-1 (Id1) during fetal embryogenesis and in different mouse and human cancer types

    Histology and Histopathology, Vol. 28, Núm. 8, pp. 1029-1040

2012

  1. The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity

    Current Medicinal Chemistry, Vol. 19, Núm. 18, pp. 3031-3043

2011

  1. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance

    Clinical Cancer Research, Vol. 17, Núm. 12, pp. 4155-4166

2010

  1. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model

    BMC Cancer, Vol. 10

2009

  1. The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer

    British Journal of Cancer, Vol. 100, Núm. 6, pp. 932-940